[
  {
    "ts": null,
    "headline": "Why Moderna Stock Has Surged 15% This Week Despite Mixed News",
    "summary": "Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market.",
    "url": "https://finnhub.io/api/news?id=a3671a41e7063b4fe9d452e693f9403e322bb7a922080aad204bedaa55e6b410",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741381449,
      "headline": "Why Moderna Stock Has Surged 15% This Week Despite Mixed News",
      "id": 133193271,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market.",
      "url": "https://finnhub.io/api/news?id=a3671a41e7063b4fe9d452e693f9403e322bb7a922080aad204bedaa55e6b410"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction",
    "summary": "Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent litigation against Moderna internationally, targeting its lipid nanoparticle technology, which could impact products like Spikevax and mRESVIA. Against this challenging backdrop, the company has kept its earnings guidance unchanged, projecting annual revenue between $1.5 billion and...",
    "url": "https://finnhub.io/api/news?id=2f8e5f025cce75990aaf7736c3e34958ec9e1e177cc3e9f87c4749b0b5105314",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741369349,
      "headline": "Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction",
      "id": 133193273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent litigation against Moderna internationally, targeting its lipid nanoparticle technology, which could impact products like Spikevax and mRESVIA. Against this challenging backdrop, the company has kept its earnings guidance unchanged, projecting annual revenue between $1.5 billion and...",
      "url": "https://finnhub.io/api/news?id=2f8e5f025cce75990aaf7736c3e34958ec9e1e177cc3e9f87c4749b0b5105314"
    }
  },
  {
    "ts": null,
    "headline": "Why Moderna Stock Has Surged 20% This Week Despite Mixed News",
    "summary": "Why Moderna Stock Has Surged 20% This Week Despite Mixed News",
    "url": "https://finnhub.io/api/news?id=c6744a97276c3198ae95d243450406bc936cd76bc03b2e8eddfe6cfe1eaecbf5",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741348689,
      "headline": "Why Moderna Stock Has Surged 20% This Week Despite Mixed News",
      "id": 133093624,
      "image": "",
      "related": "MRNA",
      "source": "DowJones",
      "summary": "Why Moderna Stock Has Surged 20% This Week Despite Mixed News",
      "url": "https://finnhub.io/api/news?id=c6744a97276c3198ae95d243450406bc936cd76bc03b2e8eddfe6cfe1eaecbf5"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals",
    "summary": "Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=24b2004c0e3a698a7c298fff5733cee9a950cc7ee110669e8566c987863a6fab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741334340,
      "headline": "The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals",
      "id": 133186695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=24b2004c0e3a698a7c298fff5733cee9a950cc7ee110669e8566c987863a6fab"
    }
  }
]